Emyria Ltd (AU:EMD) has released an update.
Emyria Ltd is progressing in the mental health and neurological sectors, having opened a new facility for MDMA-assisted therapy (MDMA-AT) and gained its first Authorised Prescriber approval, indicating a strong regulatory and clinical expertise. With a focus on PTSD treatment, the company is also advancing its drug candidates RX7/9 into animal efficacy studies while maintaining a positive cash flow from operations. Emyria’s recent successful fundraising efforts underscore investor confidence and support for its ongoing initiatives.
For further insights into AU:EMD stock, check out TipRanks’ Stock Analysis page.
